Last edition
News about "Onco3R Therapeutics "
Onco3R Therapeutics Advances Phase 1 Trial of Novel SIK3 Inhibitor Targeting Autoimmune Diseases
Pierre Raboisson, CEO and Founder of Onco3R Therapeutics, said that the final results of the Phase 1 trial of O3R-5671 are expected in the first half of 2026.
Onco3R Therapeutics | 06/10/2025 | By Dineshwori
Onco3R Therapeutics Secures Approval to Launch First-in-Human Trial of SIK3 Inhibitor O3R-5671
Onco3R Therapeutics is expected to start enrolling subjects for the first-in-human trial of SIK3 inhibitor O3R-5671 over the coming weeks, with dosing of the first subject anticipated later in September.
Onco3R Therapeutics | 04/09/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy